Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

▤ Summary

Immuneering reported updated Phase 2a data for atebimetinib combined with chemotherapy in first-line metastatic pancreatic cancer. The company highlighted a 17.3-month median overall survival in 55 patients, along with favorable tolerability and preserved weight in many participants. Immuneering also said its Phase 3 MAPKeeper 301 trial is actively recruiting and expects first patient dosing in mid-2026. The announcement underscores continued clinical momentum for its oncology pipeline and provides a near-term development milestone for the program.

▦ Linked Companies